Stress-induced activation of the hypothalamo-pituitary-adrenocortical (HPA) axis and high circulating glucocorticoid levels are well known to impair the retrieval of memory. Vasopressin can activate the HPA axis by stimulating vasopressin 1b (V1b) receptors located on the pituitary. In the present study, we investigated the effect of A-988315, a selective and highly potent non-peptidergic V1b-receptor antagonist with good pharmacokinetic properties, in blocking stress effects on HPA-axis activity and memory retrieval. To study cognitive performance, male Sprague-Dawley rats were trained on an object-discrimination task during which they could freely explore two identical objects. Memory for the objects and their location was tested 24 h later. A-988315 (20 or 60 mg/kg) or water was administered orally 90 min before retention testing, followed 60 min later by stress of footshock exposure. A-988315 dose-dependently dampened stressinduced increases in corticosterone plasma levels, but did not significantly alter HPA-axis activity of non-stressed control rats. Most importantly, A-988315 administration prevented stress-induced impairment of memory retrieval on both the object-recognition and the object-location tasks. A-988315 did not alter the retention of non-stressed rats and did not influence the total time spent exploring the objects or experimental context in either stressed or non-stressed rats. Thus, these findings indicate that direct antagonism of V1b receptors is an effective treatment to block stress-induced activation of the HPA axis and the consequent impairment of retrieval of different aspects of recognition memory.
INTRODUCTION
Stress exposure leads to an activation of the sympathetic nervous system and hypothalamo-pituitary-adrenocortical (HPA) axis, culminating in the release of catecholamines and glucocorticoids, respectively (Joëls and Baram, 2009) . These hormones are known to influence the organism's ability to cope with stress, influencing target systems in the periphery, but also inducing a myriad of effects on the brain (McEwen, 1998; de Kloet et al, 1999; McGaugh and Roozendaal, 2002) . Extensive evidence indicates that stress enhances the consolidation, but impairs the retrieval, of memory processing (reviewed in Roozendaal et al, 2009; Schwabe et al, 2012) . Although the exact biological function of stressinduced impairment of memory retrieval remains obscure (Roozendaal, 2002) , memory retrieval deficits, as a result of acute or chronic stress exposure, can have marked negative consequences for the normal cognitive functioning of an individual (de Quervain et al, 2009) . As the suppression of glucocorticoid synthesis with the 11β-hydroxylase inhibitor metyrapone prevents the impairing effect of stress exposure on memory retrieval (de Quervain et al, 1998) , these findings indicate that activation of the HPA axis and high circulating glucocorticoid levels are importantly involved in mediating stress effects on memory retrieval. This view is supported by extensive evidence that acute glucocorticoid administration before retention testing induces comparable retrieval impairment of declarative memory in humans and spatial/contextual memory in rodents (de Quervain et al, 1998 (de Quervain et al, , 2000 Roozendaal et al, 2003; Het et al, 2005; Kuhlmann et al, 2005; Atsak et al, 2012) . For decades, the predominant view held that stress has a specific and particularly robust influence on the hippocampus (McEwen and Sapolsky, 1995; Lupien and Lepage, 2001) . However, there is now emerging evidence that stress and glucocorticoids might also affect retrieval of non-hippocampal memories. A recent study indicated that stress exposure impairs retrieval of striatal-dependent stimulus-response memory in humans (Guenzel et al, 2013) . Whether and how stress exposure might also impair the retrieval of recognition memory remains largely elusive. In the present study, we used an object-discrimination task to investigate, in rats, whether stress exposure shortly before retention testing impairs recognition of different aspects of information acquired during the training phase. Specifically, the task required discrimination of a novel vs familiar object or novel vs familiar object location. Memory for the location of an object depends on the hippocampus, whereas memory for an object per se is known to rely heavily on cortical regions (Balderas et al, 2008; Roozendaal et al, 2010) .
Numerous neurotransmitter and neuropeptide systems, originating from local, brainstem, and limbic sources, are involved in modulating HPA-axis activity during stressful conditions (Rossier et al, 1979; Herman et al, 1996) . Arginine vasopressin (AVP) is a cyclic peptide that is synthesized in the hypothalamus, and it strongly contributes to the endocrine response to stress (Surget and Belzung, 2008) . During stress exposure, AVP is released from the median eminence into the pituitary portal circulation where it potentiates the effects of corticotropin-releasing factor on adrenocorticotropin (ACTH) release, which in turn stimulates glucocorticoid release from the adrenal cortex (Aguilera and Rabadan-Diehl, 2000) . Antagonism of vasopressin 1b (V1b) receptors has been reported to attenuate stressinduced HPA-axis activation (Serradeil-Le Gal et al, 2005) . The primary focus of this study was to investigate whether attenuating HPA-axis activity with the orally active nonpeptidergic V1b-receptor antagonist A-988315 is sufficient to block stress effects on memory retrieval. In contrast to adrenal steroidogenesis inhibition with metyrapone, which elevates ACTH levels triggered by reduced HPA-axis feedback regulation (Gómez et al, 1998) , direct inhibition of the HPA axis with A-988315 is expected to decrease both ACTH and corticosterone levels. This distinction might be pertinent as some evidence indicates that ACTH release or exogenous ACTH administration by itself can enhance memory retrieval (Izquierdo et al, 2002; Gisquet-Verrier et al, 2004) . As A-988315, (S)-N-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-ethoxypyridin-3-yl)-2-oxoindolin-3-yl)-4-(1-methylpiperidin-4-yl)piperazine-1-carboxamide, is a recently developed V1b-receptor antagonist, we also determined the specificity of A-988315 in binding to rat and human V1b, V1a, V2, and oxytocin receptors in vitro, and its ability to antagonize functional cellular events associated with V1b-receptor activation by AVP, such as intracellular Ca 2+ release . Moreover, we evaluated the pharmacokinetic properties of the drug after oral and intraperitoneal administration.
MATERIALS AND METHODS

Subjects
Male Sprague-Dawley rats (360-420 g at the time of training) from Charles River Breeding Laboratories (Kisslegg, Germany) were housed individually in a temperature-controlled (22°C) vivarium room (lights on: 07:00-19:00 hours) and given food and water ad libitum. Training and testing were performed during the light phase of the cycle between 10:00 and 15:00 hours, at the rat's nadir of endogenous corticosterone levels. All experimental procedures were in compliance with the European Communities Council Directive of 24 November 1986 (86/609/EEC) and approved by the Institutional Animal Care and Use Committee.
Object Training and Testing Procedures
The experimental apparatus was a gray open-field box (in cm, 40 wide × 40 deep × 40 high) with the floor covered with sawdust, positioned in a dimly illuminated room. The objects to be discriminated were transparent glass vials (5.5 cm diameter and 5 cm height) and white glass light bulbs (6 cm diameter and 11 cm length; Okuda et al, 2004; Roozendaal et al, 2010) .
All rats were handled once per day for 1 min each for 5 consecutive days preceding the training day. On the training trial, each rat was individually placed in the experimental apparatus and allowed to explore two identical objects (A1 and A2) for 10 min. To avoid the presence of olfactory cues, the sawdust was stirred and the objects were cleaned with 70% ethanol after each animal. Rats' behavior was recorded with a video camera positioned above the experimental apparatus. Videos were later analyzed by a trained observer who is blind to the treatment condition. The total time spent exploring the two objects during the training trial was taken as a measure of object exploration. Rats showing a total exploration time o20 s on the training trial were removed from analyses, because data indicated that such rats do not acquire the task (Okuda et al, 2004) .
Retention was tested 24 h after the training trial. Different groups of rats were tested on the object-recognition and object-location tasks. For object-recognition memory testing, one copy of the familiar object (A3) and a new object (B) were placed in the same location as stimuli during the training trial. For object-location memory testing, one copy of the familiar object (A3) was placed in the middle of the box (novel location) and the other familiar object (A4) was placed in the same location as during the training trial. All combinations and locations of the objects were counterbalanced to reduce potential biases owing to preference for particular locations or objects. The rat was placed in the experimental apparatus for 3 min, and the time spent exploring each object and the total time spent exploring both objects were recorded. Exploration of an object was defined as pointing the nose to the object at a distance of o1 cm and/or touching it with the nose. Turning around, climbing or sitting on an object was not considered as exploration. In order to analyze cognitive performance, a discrimination index was calculated as the difference in time exploring the novel and familiar object (or location), expressed as the ratio of the total time spent exploring both objects (ie, (time novel − time familiar/time novel+time familiar) × 100%). Exploration of the experimental apparatus was analyzed by the total number of crossings. For crossings, the floor of the box was divided into four imaginary quadrants, and the total number of crossings between quadrants during the 3-min retention test trial was determined.
Oral Drug Administration
A-988315 (20 or 60 mg/kg, free base concentration) or water, in a volume of 2 ml/kg, was orally gavaged 90 min before the retention test. A-988315 was dissolved in water.
Stress Procedure
Some rats were exposed to stress of footshock 30 min before retention testing (60 min after drug administration). We selected this time point on the basis of prior evidence that this stress procedure triggers an HPA-axis response that leads to a corticosterone plasma peak at ≈30 min (de Quervain et al, 1998) . ACTH, which is not expected to contribute significantly to stress-induced memory retrieval impairment, reaches its peak earlier (Sarabdjitsingh et al, 2010) . Rats were taken from their home cage and placed into the shock compartment of an inhibitory avoidance apparatus. The shock compartment (60 cm long, 15 cm deep, 20 cm wide at the top, and 6.4 cm wide at the bottom) was made of two electrifiable metal plates (de Quervain et al, 1998) . The rats were given a series of three inescapable footshocks (0.8 mA, 1 s in duration with an intertrial interval of 5 s). Both drug-and water-treated rats showed strong reactions to the footshocks and exhibited jumping, running, and vocalizations. Immediately after delivery of the last footshock, rats were placed back into their home cage until the retention test 30 min later. Non-stressed control rats did not receive footshock and were left undisturbed in their home cages until retention testing.
Plasma Collection, and ACTH and Corticosterone Assessment
Immediately after retention testing, rats were anesthetized with sodium pentobarbital and decapitated 90 s later. Trunk blood was collected in chilled tubes containing 30 ml aprotinin (Sigma-Aldrich) and EDTA (1.86 mg/ml blood). Blood was immediately centrifuged at 2900 g for 10 min at 4°C
, and the supernatant was stored at − 80°C. ACTH concentrations were measured by an enzyme-linked immunosorbent assay (ELISA; IBL Hamburg, Germany). Before ELISA analysis, samples were diluted 2.5-fold with calibrator A (Zero Calibrator; IBL Hamburg, Germany) provided with the ELISA kit. Corticosterone concentrations were determined with an enzyme immunoassay (EIA; Cayman chemical, purchased from Alexis GmbH, Grünberg, Germany). Plasma samples were diluted 10-fold with EIA buffer (0.2 M Na 2 HPO 4 , 0.8 M NaCl, 2 mM Na-EDTA, 0.2% w/v bovine serum albumin (BSA)) for the corticosterone assay. The intra-and inter-assay coefficients of variation for ACTH and corticosterone were o10%. The analytical sensitivity for ACTH was 0.46 pg/ml and for corticosterone was 30 pg/ml.
Statistics
Object-recognition training and retention data, and ACTH and corticosterone plasma levels are expressed as mean ± SEM. Two-way ANOVAs for discrimination index, total object exploration, number of crossings, and plasma ACTH and corticosterone levels were analyzed with A-988315 treatment and stress procedure as between-subject variables. Further analyses used Fisher's post-hoc comparison tests to determine the source of the detected significance, when appropriate. Onesample t-tests were used to determine whether the discrimination index was different from zero (ie, chance level) and thus whether memory was expressed. A probability level of o0.05 was accepted as statistical significance for all the tests.
In Vitro Binding and Functional Studies, and Pharmacokinetics
Full procedures are described in Supplementary Materials and Methods. Briefly, radioligand competition-binding assays for cloned human and rat V1b receptors were performed using [3H]-AVP (8-Arg-Vasopressin NET800, PerkinElmer, Boston) as radioligand, and membranes or cell ghosts prepared from Chinese hamster ovary (CHO) cell clones stably expressing the recombinant human and rat receptors. Recombinant cell membranes were incubated with 1.5 nM (human) and 1.0 nM (rat) [3H]-AVP for competition experiments, performed in a 50-mM Tris buffer, pH 7.4, containing 10 mM MgCl 2 and 0.1% BSA without or in the presence of A-988315 (0.1 nM-10 μM). AVP (1 μM) was used for determination of nonspecific binding. Radioactivity was measured by liquid scintillation counting (Tri-Carb, PerkinElmer, Boston). Other radioligand assays were performed for human or rat V1a receptors, human V2 receptors, and human or rat oxytocin receptors. Ki values from competition-binding experiments were determined by nonlinear regression analysis (Munson and Rodbard, 1980) .
For the assessment of antagonistic potency of A-988315, recombinant human V1b receptor-expressing CHO cells were seeded into FLIPR plates (Falcon 384 plate #353962, Becton Dickinson) and incubated overnight. Stimulation of Ca 2+ release was performed with 2 nM AVP. A-988315 (at the desired concentrations) was pre-incubated for 10 min before agonist addition. Measurements were performed using a FLIPR2 reader (Molecular Devices, Sunnyvale).
To estimate the pharmacokinetic properties of A-988315 in terms of oral bioavailability, half-life and brain-to-plasma ratio, male Sprague-Dawley rats (n = 3; Janvier, Le Genest-StIsle, France) were injected intravenously (2 mg/kg) or orally gavaged (10 mg/kg) with A-988315 dissolved in water. Blood was sampled from the tail vein after 30 min, 45 min, 1, 2, 2.5, 3, 4, 6, 8, and 24 h. For the brain distribution study, rats (n = 3 for each time point) were injected intraperitoneally with 10 mg/kg of A-988315. After 30 min, 3 or 8 h, the rats were deeply anesthetized with isoflurane, and blood was drawn via cardiac puncture. The animal was sacrificed by cervical dislocation, and the brain was removed. Plasma samples and brains were stored at − 18°C until analysis. An aliquot of plasma or homogenized whole-brain tissue was pipetted into a 96-well polypropylene plate, and proteins were precipitated with acetonitrile containing an internal standard. The plate was centrifuged at 2000 g for 10 min and the supernatant was transferred to a clean 96-well plate and diluted 1:1 with 0.1% formic acid. Samples were injected on an Acquity UPLC BEH C8 1.7 μm, 2.1 × 100 mm with an acetonitrile gradient (5-95%) with 0.1% formic acid (in water) as the second solvent, at a flow rate of 0.3 ml/min. Mass-spectrometric detection was performed on an AB SCIEX Triple Quad 5500 with a turbo-ion spray interface by multiple-reaction monitoring. Oral bioavailability and brain exposure were determined by comparing the area under the curve (AUC) from zero to the final time point measured (AUC0-t) of the two compartments.
RESULTS
In Vitro Binding Studies
A-988315 displayed high affinity in radioligand-binding assays for cloned human ( Figure 1a ) and rat ( Figure 1b) vasopressin V1b receptors. The Ki values (geomeans and 95% CI) for the human V1b, V1a, and V2 receptors, and the Stress, vasopressin 1b receptors, and memory retrieval A Barsegyan et al oxytocin receptor were 0.53 (0.39-0.71), 50 (32-62), 410000, and 8.3 (6.8-10) nM, respectively (Table 1) . The Ki values for the rat V1b and V1a receptors and the oxytocin receptor were 3.8 (2.7-5.4), 121 (102-141), and 90 (77-100) nM (Table 1) , respectively. Thus, the Ki value for the rat V1b receptor was sevenfold above that of the human V1b receptor. The Hill slopes derived from the inhibition-binding curves with the cloned human and rat V1b receptors were close to unity, suggesting a single site of interaction of A-988315 and radioligand in these membrane preparations.
Intracellular Ca 2+ Release
Antagonistic properties of A-988315 were assessed in recombinant CHO cells expressing the human V1b receptor. As shown in Figure 1c , A-988315 antagonized the AVPmediated Ca 2+ release in a concentration-dependent manner with a Kb value, as a measure of competitive antagonist potency, of 0.10 nM (geomean, 95% CI: 0.062-0.15 nM, n = 3).
Pharmacokinetic Studies
A-988315 demonstrated good pharmacokinetic properties. The oral bioavailability of the compound was 50 ± 14% (n = 3). After a single 10-mg/kg oral dose, A-988315 reached a maximal plasma concentration of 228 ± 59 ng/ml (Figure 1d ). Estimated plasma half-life of A-988315 was 5.6 ± 0.7 h. The brain:plasma ratio calculated over an 8-h time period was 0.32.
Behavioral Studies
Effect of A-988315 on stress-induced impairment of retrieval of object-recognition memory. This experiment investigated whether oral administration of A-988315 would block stress-induced impairment of retrieval of objectrecognition memory. For this, rats were exposed to a single 10-min training trial during which they could freely explore two identical objects. Retention of the training was tested 24 h later. A-988315 (20 or 60 mg/kg) or water was administered 90 min before retention testing. Some rats were exposed to stress of footshock 30 min before retention testing. During the retention test, one object was familiar and the other object was novel. Figure 2a shows the timeline of the object-recognition experiment.
Training trial. Figure 2b shows the total time spent exploring the two identical objects during the 10-min training trial (before drug treatment or shock exposure). As expected, two-way ANOVA indicated no differences between later drug treatment (F 2,55 = 1.12; NS), stress exposure (F 1,55 = 0.08; NS), or an interaction between these two parameters (F 2,55 = 0.27; NS).
Retention trial. Figure 2c shows the discrimination index during the retention test trial. Two-way ANOVA indicated a significant A-988315 effect (F 2,55 = 3.61; P = 0.03), stress-exposure effect (F 1,55 = 9.10; P = 0.004) as well as a significant interaction between these two parameters (F 2,55 = 5.14; P = 0.009). One-sample t-test indicated that the discrimination index of non-stressed control rats administered water before retention testing was significantly different from zero (ie, chance level, t 10 = 6.73; P = 0.0001), indicating that these rats readily discriminated the novel object at the 24-h retention test. A-988315 (20 or 60 mg/kg) 
Po0
.01 compared with the corresponding non-stress group. Number of rats per group-non-stress groups: water, n = 11; 20 mg/kg, n = 11; and 60 mg/kg, n = 10; and stress groups: water, n = 10; 20 mg/kg, n = 9; and 60 mg/kg, n = 10.
Stress, vasopressin 1b receptors, and memory retrieval A Barsegyan et al did not significantly alter the discrimination index of nonstressed rats (P ⩾ 0.55). Water-treated rats that were subsequently exposed to stress of footshock 30 min before retention testing showed impaired recognition of the familiar object as compared with water-treated non-stressed rats (P = 0.0003). One-sample t-test indicated that the discrimination index of water-treated stressed rats did not differ significantly from zero (t 9 = 0.57; P = 0.58), indicating that they did not show any evidence of retention of the training session. Most importantly, both doses of A-988315 (20 or 60 mg/kg) normalized the discrimination index of stressed rats (20 mg/kg: P = 0.001; 60 mg/kg: P = 0.001 vs water), which did not differ significantly from that of non-stressed rats. Further, one-sample t-tests indicated that the discrimination index of stressed rats administered A-988315 was significantly different from zero (20 mg/kg: t 8 = 6.47; P = 0.0002; 60 mg/kg: t 9 = 5.31; P = 0.0005), indicating good retention performance. Figure 2d shows total exploration of the two objects during the retention test. Two-way ANOVA indicated no significant A-988315 effect (F 2,55 = 0.75; NS), stress-exposure effect (F 1,55 = 0.00; NS) or an interaction between these two parameters (F 2,55 = 1.24; NS). Similarly, two-way ANOVA for the number of quadrant crossings during the retention test trial, as a measure of exploration of the experimental apparatus, also indicated no significant A-988315 effect (F 2,55 = 0.31; NS), stress-exposure effect (F 1,55 = 1.21; NS) or interaction between these two parameters (F 2,55 = 2.22; NS; Figure 2e ).
Effect of A-988315 on stress-induced impairment of retrieval of object-location memory. This experiment investigated, in separate groups of rats, whether oral administration of A-988315 would block stress-induced impairment of retrieval of object-location memory. For this, rats were exposed, as in the first experiment, to a 10-min training trial during which they could freely explore two identical objects. Retention of the training was tested 24 h later. A-988315 (20 or 60 mg/kg) or water was administered 90 min before retention testing, followed 60 min later by stress exposure. During the retention test, both objects were familiar, but one object was placed in a novel location. Figure 3a shows the timeline of the object-location experiment.
Training trial. Figure 3b shows the total time spent exploring the two identical objects during the 10-min training trial (before drug treatment or shock exposure). Two-way ANOVA indicated no differences between later drug-treatment groups (F 2,57 = 0.99; NS), stress-exposure effect (F 1,57 = 0.75; NS) or an interaction between these two parameters (F 2,57 = 0.71; NS).
Retention trial. Figure 3c shows the discrimination index during the retention test trial. Two-way ANOVA indicated no significant stress-exposure effect (F 1,57 = 2.54; NS), but a significant A-988315 effect (F 2,57 = 3.65; P = 0.03) as well as a significant interaction between these two parameters (F 2,57 = 5.93; P = 0.005). One-sample t-test indicated that the discrimination index of non-stressed control rats administered water before retention testing was significantly different from zero (t 9 = 3.50; P = 0.007), indicating that these rats readily discriminated the object placed in a novel location. A-988315 (20 or 60 mg/kg) did not significantly alter the discrimination index of non-stressed rats (P ⩾ 0.41). Water-treated rats that were subsequently exposed to stress of footshock (30 min before retention testing) showed impaired recognition of the location of objects during training (P = 0.003 vs water). One-sample t-test indicated that the discrimination index of water-treated stressed rats did not differ significantly from zero (t 10 = − 1.24; P = 0.24), indicating that they did not show retention of the training. Most importantly, both doses of A-988315 (20 or 60 mg/kg) normalized the discrimination index of stressed rats (20 mg/kg: P = 0.005; 60 mg/kg: P = 0.0008 vs water), and did not differ significantly from their nonstressed counterparts. Further, one-sample t-tests indicated that the discrimination index of stressed rats administered A-988315 was significantly different from zero (20 mg/kg: t 9 = 3.40; P = 0.008; 60 mg/kg: t 10 = 4.37; P = 0.001), indicating good retention performance. Figure 3d shows total exploration of the two objects during the retention test. Two-way ANOVA indicated no significant A-988315 effect (F 2,57 = 0.67; NS), stress-exposure effect (F 1,57 = 0.62; NS) or an interaction between these two parameters (F 2,57 = 0.60; NS). Two-way ANOVA for the number of crossings during the retention test trial also indicated no significant A-988315 effect (F 2,57 = 0.72; NS), stress-exposure effect (F 1,57 = 0.66; NS) or interaction between these two parameters (F 2,57 = 1.15; NS; Figure 3e ).
Effect of A-988315 on stress-induced increases in plasma ACTH and corticosterone levels. Immediately after either object-recognition or object-location memory testing, rats were sacrificed for collection of blood for measurement of plasma ACTH and corticosterone levels. Figure 4a shows plasma ACTH levels. Two-way ANOVA revealed a significant stress-exposure effect (F 1,118 = 19.32; Po0.0001), but no significant A-988315 effect (F 2,118 = 0.47; NS) or interaction between both factors (F 2,118 = 0.79; NS). A-988315 (20 or 60 mg/kg) did not significantly alter plasma ACTH levels of non-stressed rats (P ⩾ 0.85). Water-treated rats that were subsequently exposed to stress of footshock showed significantly elevated plasma ACTH levels as compared with water-treated non-stressed rats (P = 0.004). A-988315 (20 or 60 mg/kg) did not significantly reduce plasma ACTH levels as compared with water-treated stressed rats (P ⩾ 0.12). However, plasma ACTH levels of stressed rats treated with the higher dose of A-988315 were not significantly higher than those of non-stressed rats treated with the same drug dose (P = 0.15). Figure 4b shows plasma corticosterone levels. Two-way ANOVA indicated no significant drug effect (F 2,117 = 0.61; NS), but a significant stress-exposure effect (F 1,117 = 38.96; Po0.0001) and interaction between both factors (F 2,117 = 3.98; P = 0.02). A-988315 (20 or 60 mg/kg) did not significantly alter plasma corticosterone levels of non-stressed rats (P ⩾ 0.21). Water-treated rats that were subsequently exposed to stress of footshock showed significantly elevated plasma corticosterone levels as compared with water-treated nonstressed rats (Po0.0001). A-988315 dose-dependently decreased plasma corticosterone levels in stressed rats (20 mg/kg: P = 0.16; 60 mg/kg: P = 0.01). Plasma corticosterone levels of stressed rats treated with the higher dose of A-988315 did not differ significantly from those of non-stressed rats treated with the same drug dose (P = 0.12).
DISCUSSION
Stress-induced activation of the HPA axis and high circulating glucocorticoid levels are well known to impair the retrieval of memory processing (de Quervain et al, 2009) . As AVP contributes strongly to the endocrine response to stress by stimulating V1b receptors located on the pituitary, the primary aim of the present experiments was to investigate whether oral administration of the nonpeptidergic V1b-receptor antagonist A-988315 would block stress-induced HPA-axis activation and memory retrieval impairment.
As A-988315 is a newly developed compound, and lacking any published reports, we first determined its specificity in antagonizing V1b receptors in vitro. Our findings indicate that A-988315 is a potent V1b-receptor antagonist (Ki = 0.53 nM, Kb = 0.1 nM) with high selectivity vs human V1a and V2 receptors and moderate selectivity vs human oxytocin receptors. Despite a sevenfold lower affinity to rat V1b receptors, A-988315 displayed a similar selectivity at rat receptors in vitro. A-988315 was able to fully block the AVP-mediated intracellular Ca 2+ release in transfected cells indicating its antagonistic properties. Furthermore, the compound has a high plasma exposure and a half-life over 5 h indicating good pharmacokinetic properties. In addition, with an oral bioavailability of 50%, A-988315 is a good tool compound for preclinical studies suitable for oral administration. 
Po0
.01 compared with the corresponding non-stress group. Number of rats per group-non-stress groups: water, n = 10; 20 mg/kg, n = 10; and 60 mg/kg, n = 11; and stress groups: water, n = 11; 20 mg/kg, n = 10; and 60 mg/kg, n = 11.
To study whether V1b-receptor antagonism is sufficient to block the stress effects on cognitive performance, A-988315 was administered orally before stress exposure, and 90 min before retention testing on an object-recognition or objectlocation task. A-988315 did not alter HPA-axis activity or retention performance of non-stressed rats, suggesting that V1b-receptor activation does not have a major role in determining baseline HPA-axis activity and memory. A-988315 administration dampened the stress-induced increases in ACTH and corticosterone plasma levels. This effect was most pronounced with the higher drug dose. It should be noted that at the time of retention testing and blood sampling, stress-induced corticosterone plasma levels were most likely at their peak values, whereas ACTH levels were already declining (Sarabdjitsingh et al, 2010) . We opted for this 30-min time interval because of the main role of corticosterone in mediating stress effects on memory retrieval impairment (de Quervain et al, 1998) . However, the selection of this time point probably also accounts for our finding that A-988315 seems to have a less dramatic effect on footshockinduced ACTH release. Most importantly, A-988315 blocked the stress-induced impairment of memory retrieval on both the object-recognition and object-location tasks. As A-988315 and the footshock stressor were given shortly before retention testing, 24 h after the training session, the behavioral changes are not caused by stress or drug effects on the encoding or consolidation of memory. Moreover, as A-988315 administration to either stressed or control rats did not influence the total time spent exploring the objects or experimental context, the findings indicate that V1b-receptor antagonism did not restore retention performance by altering rats' incentive to explore the objects or it did not produce any other non-specific behavioral effects. Rather, our findings are consistent with the view that A-988315 blocked stress effect on memory retrieval by attenuating the impact of stress on HPA-axis activity. In support of a role of V1b receptors in modulating HPA-axis activity in influencing stress-related behaviors, Urani et al (2011) reported that the structurally related V1b-receptor antagonist SSR149415 administered before object-recognition training blocked the effect of acute stress exposure during acquisition on short-term task performance tested 1 h later. Moreover, a recent genetic study in human subjects reported an association between common V1b receptor and glucocorticoid receptor gene variants in regulating HPA-axis responses to psychosocial stress in a child psychiatric population (van West et al, 2010) . However, these prior studies did not specifically investigate the role of V1b receptors in regulating stress effects on the retrieval of memory. As evidence from both animal and human studies indicates sex dimorph stress effects on glucocorticoid release and memory retrieval (eg, Baran et al, 2009; Bentz et al, 2013) , it is important in future studies to examine the effect of A-988315 on stress-induced HPA-axis activity and memory retrieval impairment in both male and female rats.
AVP is released during stressful conditions and acts as a direct ACTH secretagogue and also potentiates the stimulatory effects of corticotropin-releasing factor on HPA-axis activity (Aguilera and Rabadan-Diehl, 2000; Surget and Belzung, 2008) . Our finding that even the higher dose of A-988315 did not fully block stress-induced HPA-axis activity suggests that the drug might have additional effects of relevance in preventing stress-induced memory retrieval impairment. In addition to a peripheral mechanism of action, the V1b receptor is expressed in hippocampal CA2 pyramidal neurons, and to some extent in the hypothalamus and the amygdala (Barberis and Tribollet, 1996; Hernando et al, 2001; Young et al, 2006) . Although the large majority of studies investigating the central effects of AVP on cognitive performance have focused on V1a receptor-mediated mechanisms (de Wied et al, 1993) , some evidence suggests a putative involvement of central V1b receptors in regulating certain behaviors during affective states. Rodent studies indicated that peripheral as well as central pretreatment with the V1b-receptor antagonist SSR149415 reduces anxiety-and depression-related behaviors SerradeilLe Gal et al, 2002; Roper et al, 2011) . Moreover, there is some evidence that V1b-receptor activation is involved in regulating aggressive and social behaviors. It has been reported that mice lacking a functional V1b receptor are deficient in sociability and detecting social novelty (Caldwell et al, 2008; Stephenson and Caldwell, 2012; Pagani et al, 2014) . It is Figure 4 Effect of pretest administration of A-988315 on stress-induced increases in plasma ACTH and corticosterone levels. (a) Plasma ACTH levels (in pg/ml) as assessed immediately after the memory retrieval test. (b) Plasma corticosterone levels (in ng/ml) of rats as assessed immediately after the memory retrieval test. All data are expressed as mean+SEM. *Po0.05 compared with the corresponding water group.
♦♦ Po0.01 compared with the corresponding non-stress group. Number of rats per group-non-stress groups: water, n = 21; 20 mg/kg, n = 21 for ACTH, n = 20 for corticosterone; 60 mg/kg, n = 21; and stress groups: water, n = 21; 20 mg/kg, n = 19; 60 mg/kg, n = 21.
Stress, vasopressin 1b receptors, and memory retrieval A Barsegyan et al unclear, however, whether these behavioral alterations are produced completely independently from the effects of V1b-receptor activation on the HPA axis. Some evidence further suggests that V1b receptors might have a role in hippocampal neural plasticity (Pagani et al, 2014) and hippocampusdependent memory for temporal order (DeVito et al, 2009) . Consistent with the present findings, mice lacking the V1b receptor showed normal recognition of previously explored objects and remembered where they were experienced; however, they displayed a very specific impairment in remembering the hippocampus-dependent temporal order of presentation of those objects (DeVito et al, 2009) . Our finding that stress exposure shortly before retention testing impaired the retrieval of object-recognition and object-location memory is consistent with other evidence indicating that the same footshock stress procedure impaired rats' retrieval of spatial memory in a water maze (de Quervain et al, 1998) . Moreover, acute mild stress exposure to humans is known to impair delayed recall performance (Kuhlmann et al, 2005) . Prior studies have, however, predominantly investigated the effects of stress or elevated glucocorticoid levels on retrieval of hippocampus-dependent 'declarative' memories in humans or spatial/contextual memories in rodents (de Quervain et al, 1998 (de Quervain et al, , 2000 Roozendaal et al, 2003; Het et al, 2005; Kuhlmann et al, 2005; Atsak et al, 2012) . A small number of studies examined the effect of glucocorticoids on both free recall of information and recognition performance (de Quervain et al, 2000 Domes et al, 2004; Buchanan et al, 2006) . One study found that stress-induced cortisol secretion impaired recognition for positive, but not negative or neutral, word associations (Domes et al, 2004) , whereas the findings of the other studies indicated that stress and/or glucocorticoids significantly impaired free recall performance, yet induced only a small and nonsignificant recognition impairment. Such findings have often been interpreted in favor of a preferred influence of stress and glucocorticoids on the hippocampus (Lupien and Lepage, 2001) . Alternatively, as recognition scores in human studies are often close to ceiling, it is possible that the absence of a significant stress effect was observed because the memory task had been calibrated specifically to detect impairment in free recall, and consequently, a recognition task for the same items was not sufficiently demanding. Here we provide strong evidence that stress exposure produced a large and significant impairment in the retrieval of different aspects of recognition memory. Memory for the location of an object is known to depend on the hippocampus, whereas memory for an object per se relies heavily on cortical regions and does not appear to depend critically on the hippocampus (Balderas et al, 2008; Roozendaal et al, 2010) . It should be noted, however, that one study reported that although object recognition was intact after dorsal hippocampal lesions that damaged 50-75% of total hippocampal volume, it was impaired after very large lesions that encompassed 75-100% of hippocampal volume (Broadbent et al, 2004) . Our findings suggest, therefore, that stress and elevated glucocorticoid levels might have a broad effect on the brain in influencing retrieval of different forms of memory. Such findings are consistent with a very recent study indicating that exposure to a social-evaluative stressor impaired retrieval of striataldependent stimulus-response memory in healthy human volunteers (Guenzel et al, 2013) .
In addition to the deleterious consequences of acute stress exposure on memory retrieval, several clinical conditions, such as chronic stress, major depression, and Cushing's syndrome, are associated with persistently elevated HPA-axis activity, hypercortisolemia, and memory impairment (Starkman et al, 1992) . Metyrapone is an orphan medication that holds the FDA approval for the diagnosis of Cushing's syndrome and is occasionally used off-label for short-term treatment of Cushing's syndrome before surgery. However, treatment with metyrapone or other steroidogenic inhibitors is usually discouraged because of poor tolerability and the contradictory increase in ACTH production and mineralocorticoid effects (Díez and Iglesias, 2007; Traina et al, 2013) . Therefore, alternative medical treatments for the curtailing of HPA-axis activity are needed. In chronic stress, the expression of AVP in parvocellular neurons of the paraventricular nucleus and its secretion into pituitary portal circulation increase. In addition, stress regulates pituitary V1b receptors, increasing the corticotropin-releasing activity of AVP (Rabadan-Diehl et al, 1995) . Future research should explore the suitability of direct antagonism of V1b receptors on the pituitary, which does not increase ACTH levels, as an alternative treatment option in patients with hyperactivation of the HPA axis (Roper et al, 2011) . Such pharmacological intervention might be particularly relevant for individuals who are carriers of specific V1b receptor gene variants, associated with increased sensitivity to AVP, and display an increased vulnerability to stress-related mood and anxiety disorders (Ben-Efraim et al, 2013) .
In conclusion, the present findings indicate that oral administration of the non-peptidergic V1b-receptor antagonist A-988315 before retention testing reduces the effect of stress on the HPA axis and blocks stress-induced impairment of retrieval of different aspects of recognition memory.
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